Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CTSV | O60911 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295685 | 0.92 | CYP19A1 (0.64) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL15814442 | 0.90 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL31418722 | 0.88 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL371728 | 0.88 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL3296055 | 0.85 | CYP19A1 (0.64) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL3295745 | 0.85 | CYP19A1 (0.62) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL3295755 | 0.85 | CYP19A1 (0.62) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL3295922 | 0.85 | CYP19A1 (0.64) | MEN1KMT2AMAPTCYP19A1HTT | |
| SCHEMBL3297599 | 0.85 | CYP19A1 (0.62) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL544956 | 0.84 | MEN1 (0.61) | MEN1KMT2AMAPTCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741520-B2 | Sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741520-B2 | Sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1984325-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007120379-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1172356-B1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-07 | — | — | US | disclosed |
| EP-1172356-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-6165683-A | Metallized azo-ether dyes for optical recording layers | EASTMAN KODAK COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0649880-B1 | Metallized azo-ether dyes for optical recording layers | EASTMAN KODAK CO (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0649884-B1 | Dye mixtures for optical recording layers | EASTMAN KODAK CO (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5500325-A | Dye mixtures for optical recording layers | EASTMAN KODAK COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0649884-A1 | Dye mixtures for optical recording layers | EASTMAN KODAK COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
| EP-0649880-A1 | Metallized azo-ether dyes for optical recording layers | EASTMAN KODAK COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | MEN1 4161/4885KMT2A 4213/4885MAPT 268/4885 |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | CYP19A1, AR, SULT2A1 | MEN1 3204/4885KMT2A 190/4885MAPT 4778/4885 |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | NAAA, NAT1, ACOT7 | MEN1 1076/4885KMT2A 513/4885MAPT 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.